NDAINJECTIONINJECTABLEPriority Review
Approved
Jul 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TALWIN (pentazocine lactate) is an injectable opioid analgesic approved in 1967 for moderate to severe pain management. It is a mixed opioid agonist-antagonist administered via intramuscular, intravenous, or subcutaneous injection. The drug has been a long-standing option in acute pain settings, particularly in hospital and emergency care environments.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), the brand team is likely focused on defending core institutional accounts rather than growth; expect smaller, specialized teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TALWIN offers limited career growth potential given its LOE-approaching lifecycle and minimal linked job openings (0 identified). Roles are concentrated in commercial and medical affairs, focused on defending market share in institutional settings rather than innovation.
Brand ManagerMedical Science Liaison
Worked on TALWIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.